NEW YORK (GenomeWeb News) – Pacific Biosciences reported after the close of the market Tuesday that its fourth quarter 2013 revenues grew 54 percent year over year and 23 percent sequentially.

The Menlo Park, Calif.-based single-molecule sequencing technologies firm reported Q4 revenues of $9.1 million, compared to just $5.9 million in Q4 2012 and up from $7.4 million in Q3 2013. It matched the consensus Wall Street estimate.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.